Purple Biotech Ltd ADR Dossier
Qualitative Analysis
Business overview
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage biotechnology company headquartered in Rehovot, Israel, dedicated to developing first-in-class immunotherapies designed to overcome tumor immune evasion and drug resistance in difficult-to-treat cancers. The company's core focus is its next-generation CAPTN-3 tri-specific antibody platform, which features its lead therapeutic candidate IM1240 (targeting 5T4, capped-CD3, and NKG2A) and its second candidate IM1305 (targeting TROP2). Additionally, the company's pipeline includes two clinical-stage oncology assets, CM24 (a monoclonal antibody blocking CEACAM1) and NT219 (a dual IRS1/2 and STAT3 inhibitor), which are currently paused for further development pending strategic partnerships or investments.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Refocusing corporate resources and development priorities entirely on the CAPTN-3 next-generation tri-specific antibody platform (including candidates IM1240 and IM1305), while pausing internal development of clinical-stage assets CM24 and NT219 unless strategic partnerships or investments are secured.
Expected impact: Maximizing anti-cancer potency while minimizing toxicity through conditional activation, and optimizing resource allocation to extend the cash runway into 2027.
Collaborating with Converge Bio to apply advanced generative AI capabilities to accelerate and enhance the design, optimization, and developability profiles of next-generation tri-specific antibodies.
Expected impact: Significantly reducing discovery timelines, improving candidate quality, and expanding CAPTN-3's capabilities against additional high-value solid tumor targets.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Integrates Converge Bio's proprietary generative AI platform with Purple Biotech's CAPTN-3 conditional activation technology to optimize T-cell engagers and accelerate discovery timelines.
Terms: Specific financial terms were not publicly disclosed.
Generating efficacy data in patient-derived tumor explants to validate the anti-tumor activity and the critical role of the NKG2A arm of IM1240.
Terms: Specific financial terms were not publicly disclosed.